Dr. Logothetis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Unit 1274, Box 301439
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1978 - 1979
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1977 - 1978
- University of AthensClass of 1974
Certifications & Licensure
- FL State Medical License 2021 - Present
- MI State Medical License Current
- AZ State Medical License 2023 - 2025
- WA State Medical License 2023 - 2025
- LA State Medical License 2023 - 2024
- GA State Medical License 2023 - 2024
- OK State Medical License 2020 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2003-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma Start of enrollment: 2000 Oct 01
- Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases Start of enrollment: 2003 May 01
- Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 Start of enrollment: 2003 May 01
- Join now to see all
Publications & Presentations
PubMed
- Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series.Nicolas Anselmino, Estefania Labanca, Peter D A Shepherd, Jiabin Dong, Jun Yang, Xiaofei Song, Subhiksha Nandakumar, Ritika Kundra, Cindy J Lee, Nikolaus Schultz, Jian...> ;Clinical Cancer Research. 2024 Mar 15
- Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Prog...Wassim Abida, Andrew W Hahn, Neal Shore, Neeraj Agarwal, Paul Sieber, Matthew R Smith, Tanya Dorff, Paul Monk, Matthew Rettig, Rupal Patel, Anne Page, Maureen Duff, Ro...> ;Clinical Cancer Research. 2024 Mar 15
- Bone mimetic environments support engineering, propagation, and analysis of therapeutic response of patient-derived cells, ex vivo and in vivo.Paindelli, C., Parietti, V., Barrios, S., Shepherd, P., Pan, T., Navone, N., Mikos, A., Dondossola, E., Wang, W., Logothetis, C., Campbell, M., Satcher, R.> ;Acta Biomaterialia. 2024 Feb 20
- Join now to see all
Press Mentions
- MD Anderson Research Highlights for September 8, 2021September 8th, 2021
- Study Identifies Possible New Combination Chemotherapy for Patients with Advanced Prostate CancerMay 30th, 2015
- I Started Researching Prostate Cancer and Scared the Hell Out of MyselfApril 28th, 2014
- Join now to see all
Grant Support
- M D Anderson Cancer Center Prosate SporeNational Cancer Institute2009–2011
- Administrative CoreNational Cancer Institute2009–2011
- University Of Texas Spore In Prostate CancerNational Cancer Institute2001–2007
- Pilot--Developmental Research ProgramNational Cancer Institute2001–2002
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: